PURPLE BIOTECH LTD-ADR

PPBTNASDAQ

US Equity

$157.35▲ $5.66 (+3.60%)

Simulated price

🔔

Track PPBT

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 3.6%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$333.07B

Large Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

10.6x

Elevated

Otter Score

Fair

No chart data available for PPBT.

Trading Snapshot

Day Range: $155.87 – $158.44
52-Week Range: $1.00 – $2.20
Volume: $4.00B
Avg Volume: $3.61B
Shares Outstanding: 3.24B
Next Earnings: Oct 20, 2026

Fundamentals Snapshot

Annual Revenue: $62.84B
Last Q Revenue: $15.74B
P/E Ratio: —
P/S Ratio: 10.6x
EPS (TTM): $-0.01
Dividend Yield: —
Dilution (1yr): +480.5%

Why Investors Own PPBT

✓High-growth profile — revenue up +3.5% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PURPLE BIOTECH LTD-ADR

PPBT

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$27M▲ +149.5% YoY

Free Cash Flow

−$6M▼ −61.4% YoY

Shares Outstanding

11.9M▲ +480.5% YoY

Net Cash

$8M▲ +$1M YoY

StockOtter · stockotter.space

About PURPLE BIOTECH LTD-ADR

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.

🦦